Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bullous pemphigoid can look like erythema multiforme, so awareness is needed for proper treatment.

This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.

This review summarizes the pharmacology, mechanisms, and clinical efficacy of topical immunotherapy for alopecia areata but reports no new clinical results.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

This review reports no new results and discusses various topical treatments, noting that fluocortin butyl ester offers anti-inflammatory effects without systemic side effects, while combinations outperform single-agent therapies in managing hyperpigmentation.

This study found that Polygoni multiflori Radix water extracts accelerated hair regrowth and hair follicle development in mice, showing a safer profile compared to minoxidil.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This study described three cases of follicular mucinosis and observed that one case responded rapidly to systemic corticosteroids, suggesting a potential therapeutic effect.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

This review discusses various genetic and acquired conditions associated with poliosis circumscripta and reports no new clinical results.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This study found that paclitaxel poliglumex induces significantly less and milder alopecia compared with standard taxanes in ovarian and breast cancer patients.

This study found that liposomes coated with cationic polymers, chitosan and Eudragit EPO, showed improved physicochemical stability and enhanced skin diffusion of aciclovir and minoxidil compared to uncoated liposomes.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.

This meta-analysis found that a combination of clobetasol, hydroxychloroquine, and N-acetylcysteine may be the most effective treatment approach for lichen planopilaris compared to other therapies.

This study documented the progression of exfoliative cutaneous lupus erythematosus in German shorthaired pointers and found generally poor responses to therapies, including immunomodulatory drugs and a TNF-α inhibitor.

This review discusses the interplay between dermatology and psychology in psychodermatology, highlighting the impact of neuroendocrine stress pathways on skin diseases and the importance of considering skin of color.

TLR7-based compounds may help manage chemotherapy-induced hair loss.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

Adequate steroid treatment needed to limit bone loss in PMR patients.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

This study found that novel MPC inhibitor analogues with specific chemical modifications promoted significant hair growth in shaved mice when applied topically.

Alopecia areata often recurs after treatment with diphenylcyclopropenone.

In this case report, a patient with Crohn's disease experienced alopecia and psoriasiform reactions attributed to anti-TNF therapy, which improved after switching to Ustekinumab.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.